QIAGEN: Number of Employees 2010-2022 | QGEN

Interactive chart of QIAGEN (QGEN) annual worldwide employee count from 2010 to 2022.
  • QIAGEN total number of employees in 2021 was 6,000, a 6.95% increase from 2020.
  • QIAGEN total number of employees in 2020 was 5,610, a 10.09% increase from 2019.
  • QIAGEN total number of employees in 2019 was 5,096, a 2.91% increase from 2018.
  • QIAGEN total number of employees in 2018 was 4,952, a 5.63% increase from 2017.
QIAGEN Annual Number of Employees
2021 6,000
2020 5,610
2019 5,096
2018 4,952
2017 4,688
2016 4,684
2015 4,559
2014 4,339
2013 4,015
2012 3,999
2011 3,938
2010 3,587
2009 3,495
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.280B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00